Baystate Wealth Management’s AstraZeneca AZN Stock Holding History

Baystate Wealth Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$25.8K	Buy	192 +14	+8%	+$1.82K	﹤0.01%	506
2023 Q3	$24.1K	Sell	178 -8	-4%	-$1.09K	﹤0.01%	450
2023 Q2	$26.7K	Hold	186	–	–	﹤0.01%	419
2023 Q1	$25.9K	Buy	186 +12	+7%	+$1.61K	﹤0.01%	425
2022 Q4	$24K	Hold	174	–	–	﹤0.01%	428
2022 Q3	$19K	Buy	174 +1	+0.6%	+$127	﹤0.01%	433
2022 Q2	$23K	Hold	173	–	–	﹤0.01%	426
2022 Q1	$23K	Buy	173 +2	+1%	+$240	﹤0.01%	428
2021 Q4	$20K	Sell	171 -310	-64%	-$36.5K	﹤0.01%	469
2021 Q3	$58K	Buy	+481	New	+$56K	0.01%	283

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Baystate Wealth Management's AZN Position: Q4 2023 in Review

Baystate Wealth Management increased its AstraZeneca (AZN) stake by 7.9% in Q4 2023, buying an estimated $1.82K and bringing the position to 192 shares worth $25.8K. The position accounts for ﹤0.01% of the portfolio, ranked #506.

Baystate Wealth Management first reported a position in AZN in Q3 2021 and has held it in 10 quarters since. The position peaked at $58K in Q3 2021. 1,130 funds tracked by Wall St. Rank hold AZN as of Q4 2023.

Baystate Wealth Management held 192 shares of AstraZeneca worth $25.8K as of Q4 2023.
Baystate Wealth Management bought 14 AstraZeneca shares in Q4 2023, an estimated $1.82K.
AstraZeneca made up ﹤0.01% of Baystate Wealth Management's portfolio in Q4 2023, its #506 holding.
Baystate Wealth Management first reported a position in AstraZeneca in Q3 2021 and has held it in 10 quarters since.
Baystate Wealth Management's AstraZeneca position peaked at $58K in Q3 2021.
1,130 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2023.

Based on Baystate Wealth Management's 13F filing for Q4 2023, filed 29 Jan 2024.